Corporate ActionJun 8, 2026, 10:16 AM
HCW Biologics Files S-1 for Resale of 5.7M Shares; Gains Nasdaq Bid Price Exception
AI Summary
HCW Biologics Inc. has filed an S-1 registration statement for the resale of up to 5,693,950 shares of common stock by selling stockholders. This includes shares from a recent PIPE transaction and warrants. The company also received a Nasdaq exception to regain compliance with the minimum bid price rule by July 29, 2026, and elected to terminate a license agreement with Wugen Inc.
Key Highlights
- HCW Biologics Inc. filed an S-1 registration statement for the resale of up to 5,693,950 shares of common stock by selling stockholders.
- The filing includes shares issued in a PIPE transaction on May 22, 2026, and shares issuable upon exercise of pre-funded and common stock warrants.
- The PIPE transaction on May 21, 2026, involved 2,846,975 units at $1.405 per unit, raising approximately $4.0 million in gross proceeds.
- Directors and executive officers purchased approximately $600,000 of securities in the PIPE transaction.
- HCW Biologics Inc. received a Nasdaq exception to regain compliance with the Bid Price Rule by July 29, 2026.
- The company elected to terminate its exclusive worldwide license agreement with Wugen Inc. for ex vivo rights to HCW9201 and HCW9206.
Price Impact
More from HCWB